Intuitive Surgical heads into its third-quarter report with a split personality. The financial engine is humming, with margins climbing and cash flow surging, but the metric that ultimately drives the franchise, US da Vinci procedure growth, has been cooling for three straight quarters. The stock has rallied hard since the last report anyway, which means the October 20 release, due after the close, has to show that the procedure slowdown is leveling off rather than extending.

Wall Street expects non-GAAP earnings of $2.61 a share on revenue of about $2.88 billion, a roughly 15% increase from the year-ago $2.51 billion. That is still strong growth for a company of this size, though it is a step down from the 19% pace of the second quarter. Revenue is also expected to come in essentially flat with last quarter's $2.89 billion, consistent with management's warning about a tougher US comparison and international holiday seasonality shifting into the back half. Earnings are another matter. The consensus implies a jump from $2.37 last quarter and about 33% growth from the year-ago $1.96, so the Street is leaning heavily on margin expansion to carry the quarter. The whisper number of $2.65 sits a few cents above consensus, a modestly higher bar but not a dramatic one.

The margin story has earned that confidence. Management has lifted its non-GAAP gross margin outlook three times in a row, most recently to 68% to 69%, citing product cost reductions, fixed-cost leverage and a tariff refund, while operating expense growth guidance has been narrowed to 11% to 13%. A gross margin that holds near the top of that range without the help of a one-time refund would validate the view that profitability gains are structural. Signs of slippage would raise the question of how much of the recent strength was borrowed.

Demand is where the real test lies. US procedure growth slowed to 12% last quarter from 14% in the first quarter and 16% a year earlier, and management blamed deferrable benign procedures, the expiration of enhanced ACA premium subsidies and continued GLP-1 pressure on bariatrics. More telling, the full-year procedure growth range of 13.5% to 15.5% was kept intact, but management signaled results would land nearer the middle, replacing the raise cadence of earlier in the year. A US figure that stabilizes around 12% or improves would suggest those headwinds have been absorbed. Another meaningful step down would challenge the midpoint outlook and could pull the full-year range lower. Revenue per procedure deserves attention as well, after slipping to roughly $1,830, especially with the lower-cost Extended Use Program instruments expected to pressure that metric through 2027.

There are offsets worth tracking. System placements rose 18% last quarter, helped by trade-ins and dual-console da Vinci 5 demand, and single-port procedures grew 61%. Japan's new reimbursement, effective in June, should show up more fully this quarter, and record ambulatory surgery center placements hint at a new channel. China remains the weak spot, with policy changes, quota uncertainty and local competition limiting placements to a trickle.

Sentiment has warmed considerably, with the bearish reading easing to 7.8% from 33.3% ahead of the last report, and the shares are up 16.2% since then, beating the S&P 500 by 11 percentage points. At about $424, the stock is pressing against its post-earnings high of $427.53, after recovering from a low near $329, though it still sits below its 200-day moving average around $444. That positioning leaves less room for disappointment. The verdict will hinge on whether US procedure growth holds firm enough to support the midpoint guide, because rising margins can sustain the earnings narrative only as long as the underlying demand engine stops decelerating.